A woman in the Oxford Biomedica lab
(Picture: Oxford Biomedica)The chief executive of Oxford Biomedica has hailed an “exceptional” year as a deal to manufacture Britain’s Covid-19 vaccine boosted revenues and led to a string of deals.
Revenues jumped 63% last year to £142 million, as a partnership with AstraZeneca led to surging business. Operating profits rose from £7.3 million to £35.9 million in 2021.
